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95th percentile harbor an identifiable mutation. 
We similarly identified such a mutation in only 2% 
of adults, ascertained solely on the basis of an 
observed LDL cholesterol level of at least 190 mg 
per deciliter (approximately 5 mmol per liter).1
However, we question the authors’ statement 
that “a person who has a familial hypercholes-
terolemia mutation but does not have a raised 
cholesterol level is unlikely to have an excess risk 
of cardiovascular disease.” We recently deter-
mined that for any given observed LDL choles-
terol level, those with a familial hypercholester-
olemia mutation are at substantially increased 
risk for coronary artery disease as compared 
with those without a mutation.1 It is likely that 
this increased risk reflects increased cumulative 
exposure to LDL cholesterol mediated by a ge-
netic mutation that has been present since birth.
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To the Editor: In their prospective study of 
screening for familial hypercholesterolemia in 
childhood, Wald et al. adopt a more relaxed case 
definition than did Wald and his fellow authors 
in their earlier meta-analysis of case–control 
data.1 In defining a case as either carriage of a 
familial hypercholesterolemia mutation or a per-
sistently high cholesterol level, the authors risk 
mixing polygenic hypercholesterolemia with mono-
genic familial hypercholesterolemia.2,3
The use of cholesterol both in the test and the 
case definition also complicates the assessment 
of screening performance. In a more orthodox 
subsidiary analysis (see Table S3 in the Supple-
mentary Appendix of Wald et al. [Oct. 27 issue]), 
the detection rate for a familial hypercholester-
olemia mutation was lower and the false positive 
rate higher than previously estimated.1 However, 
the high biochemical false positive rate could be 
mitigated by the next-generation sequencing of 
four genes known to cause familial hypercholes-
terolemia in samples that exceed the threshold 
for cholesterol screening.
Such a two-stage screen would detect carriers 
of familial hypercholesterolemia with the high-
est cholesterol levels (and the greatest risk of 
coronary disease), allow mutation-based testing 
of first-degree relatives, and avoid screening for 
polygenic hypercholesterolemia, for which con-
ventional treatment is based on absolute risk. 
Lowering the cholesterol-screening threshold 
would increase the sequencing burden but would 
also increase the detection rate for mutation-
positive familial hypercholesterolemia without 
compromising the overall rate for false positives.
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The authors reply: Dividing familial hypercho-
lesterolemia mutations into the categories of patho-
genic and nonpathogenic is necessarily impre-
cise and often arbitrary. The main indicator of 
pathogenicity is probably the extent to which a 
familial hypercholesterolemia mutation is asso-
ciated with a high LDL (or total) cholesterol level, 
since it is the high LDL cholesterol level that in-
creases the risk of myocardial infarction. Our 
study, unlike the database noted by Kullo and 
Safarova,1 was based on an unselected population 
and therefore provided an unbiased indicator of 
the prevalence of familial hypercholesterolemia 
mutations in persons without high cholesterol 
levels. Our results and the database both show 
that a substantial proportion of people with fa-
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